# LITESPARK-011 (belzutifan): what clinicians are saying

> 1,422 statements from 239 sources (23 podcasts, 23 videos, 189 posts, 3 papers, 1 registry record), 672 of them from 61 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026.

## Report

- Trial: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
- NCT ID: NCT04586231
- Registry: https://clinicaltrials.gov/study/NCT04586231
- Sponsor: Merck Sharp & Dohme LLC
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: belzutifan plus lenvatinib
- Indication: advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy
- Version: v1.0.0, edition 1
- Accepted: 2026-11-20 UTC
- Last checked: 2026-11-20 UTC
- Release hash: ce78c477cbba2f6321231571af1104f3f62ec64d9fd5710d8ff30c6529e2177f

## Counts

- Commentary sources screened: 461
- Sources cited by verified statements: 239
- Verified statements: 1,422
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 672
- Findings: 12
- Named people in screened sources (unnamed speakers and accounts not counted): 95
- Speakers cited: 92
- Cited speakers with a verified identity: 75
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 61
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 60
- By role and specialty (the abstract's specialty counts):
  - 36 physician, Medical oncology
  - 18 physician, specialty not confirmed
  - 2 physician, Hematology and oncology
  - 2 physician, Urology
  - 1 pharmacist
  - 1 physician, Internal medicine
  - 1 physician, Surgical oncology
- Organisational or shared accounts (not counted as people): 28

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

One physician reads LITESPARK-011 as grounds to change practice because responses lasted longer, while acknowledging that survival benefit remains unproven. Another physician favors earlier belzutifan–lenvatinib because patients may never reach later treatment lines. A medical oncologist still leans toward single-agent treatment for most patients, citing difficulty delivering lenvatinib, and wants cardiac toxicity better understood. Comparisons with lenvatinib–everolimus and sequential treatment remain unresolved.

## Question clinicians left open

What do clinicians say would justify adopting belzutifan plus lenvatinib as a standard for advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy—PFS and response balanced against toxicity, or mature overall survival evidence?

From finding F1 (7 statements from 6 speakers in 6 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. LITESPARK-011: where speakers split on adoption without a proven OS benefit
  - 7 statements from 6 speakers in 6 sources, 2 of them podcasts or videos.
  - 6 of the 6 named speakers in this finding take a side on this question: 5 on one side, 2 on the other, 1 on both.
  - 4 of the report's 61 cited clinicians.
- F2. Durable responses and PROs: where speakers split on evidence of patient benefit
  - 78 statements from 27 speakers in 41 sources, 19 of them podcasts or videos.
  - 0 of the 27 named speakers in this finding take a side on this question: 0 on one side, 0 on the other.
  - 18 of the report's 61 cited clinicians.
- F3. Care: where speakers split on toxicity but weigh fitness, dosing and heart checks
  - 145 statements from 37 speakers in 66 sources, 25 of them podcasts or videos.
  - 0 of the 37 named speakers in this finding take a side on this question: 0 on one side, 0 on the other.
  - 27 of the report's 61 cited clinicians.
- F4. IMDC risk: why some speakers keep subgroup signals exploratory and seek biomarkers
  - 83 statements from 16 speakers in 31 sources, 17 of them podcasts or videos.
  - 4 of the 16 named speakers in this finding hold this view.
  - 11 of the report's 61 cited clinicians.
- F5. Belzutifan: what speakers say
  - 23 statements from 9 speakers in 13 sources, 8 of them podcasts or videos.
  - 7 of the report's 61 cited clinicians.
- F6. Active control: why most speakers value it, but some flag evidence limits
  - 78 statements from 20 speakers in 37 sources, 22 of them podcasts or videos.
  - 13 of the 20 named speakers in this finding hold this view; 10 of the 20 hold its caveat, “some flag evidence limits”.
  - 13 of the report's 61 cited clinicians.
- F7. HIF-2α pairings: why most speakers seek validation as some weigh intensity
  - 196 statements from 42 speakers in 72 sources, 26 of them podcasts or videos.
  - 29 of the 42 named speakers in this finding hold this view; 12 of the 42 hold its caveat, “as some weigh intensity”.
  - 30 of the report's 61 cited clinicians.

### Beyond the trial population

- F8. Drugs or trials: how clinicians weigh urgency, AEs, access, later lines and evidence
  - 73 statements from 12 speakers in 10 sources, 7 of them podcasts or videos.
  - 10 of the 12 named speakers in this finding take a side on this question; every named speaker in this finding is a confirmed clinician.
  - 12 of the report's 61 cited clinicians.
- F9. IO: most clinicians weigh timing, withdrawal and local Rx but oppose routine reuse at PD
  - 140 statements from 12 speakers in 18 sources, 14 of them podcasts or videos.
  - 9 of the 12 named speakers in this finding hold this view, each a confirmed clinician; 6 of the 12 hold its caveat, “oppose routine reuse at PD”.
  - 11 of the report's 61 cited clinicians.
- F10. Belzutifan: why most clinicians favor ESAs as most weigh thresholds and risk
  - 85 statements from 10 speakers in 12 sources, 11 of them podcasts or videos.
  - 6 of the 10 named speakers in this finding hold this view, each a confirmed clinician; 6 of the 10 hold its caveat, “as most weigh thresholds and risk”.
  - 10 of the report's 61 cited clinicians.
- F11. Hypoxia: where clinicians split on holds but use lung checks, oximetry and guidance
  - 47 statements from 8 speakers in 8 sources, all podcasts or videos.
  - 0 of the 8 named speakers in this finding take a side on this question: 0 on one side, 0 on the other; every named speaker in this finding is a confirmed clinician.
  - 8 of the report's 61 cited clinicians.
- F12. Belzutifan: some clinicians seek markers; some question a VHL-negative veto
  - 61 statements from 7 speakers in 8 sources, 7 of them podcasts or videos.
  - 3 of the 7 named speakers in this finding hold this view, each a confirmed clinician; 2 of the 7 hold its caveat, “some question a VHL-negative veto”.
  - 6 of the report's 61 cited clinicians.

5 of the 12 findings and 345 of the 1,422 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 7 | 9 | 6 | 6 | 2 |
| F2 | 78 | 61 | 41 | 27 | 3 |
| F3 | 145 | 114 | 66 | 37 | 3 |
| F4 | 83 | 79 | 31 | 16 | 3 |
| F5 | 23 | 26 | 13 | 9 | 4 |
| F6 | 78 | 67 | 37 | 20 | 2 |
| F7 | 196 | 150 | 72 | 42 | 2 |
| F8 | 73 | 100 | 10 | 12 | 6 |
| F9 | 140 | 120 | 18 | 12 | 2 |
| F10 | 85 | 73 | 12 | 10 | 3 |
| F11 | 47 | 43 | 8 | 8 | 2 |
| F12 | 61 | 52 | 8 | 7 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 7 | 0 | 0 | 0 | 0 | 9 | 0 | 4 posts and articles, 2 podcasts and video |
| F2 | 46 | 2 | 2 | 14 | 14 | 83 | 4 | 22 posts and articles, 19 podcasts and video |
| F3 | 85 | 18 | 12 | 17 | 13 | 159 | 22 | 41 posts and articles, 25 podcasts and video |
| F4 | 48 | 23 | 1 | 3 | 8 | 105 | 19 | 14 posts and articles, 17 podcasts and video |
| F5 | 15 | 5 | 1 | 1 | 1 | 33 | 5 | 5 posts and articles, 8 podcasts and video |
| F6 | 48 | 6 | 1 | 3 | 20 | 88 | 5 | 15 posts and articles, 22 podcasts and video |
| F7 | 102 | 33 | 0 | 16 | 45 | 224 | 32 | 46 posts and articles, 26 podcasts and video |
| F8 | 37 | 10 | 11 | 3 | 12 | 107 | 26 | 3 posts and articles, 7 podcasts and video |
| F9 | 81 | 30 | 14 | 2 | 13 | 172 | 63 | 4 posts and articles, 14 podcasts and video |
| F10 | 27 | 11 | 35 | 1 | 11 | 98 | 22 | 1 post or article, 11 podcasts and video |
| F11 | 21 | 5 | 13 | 0 | 8 | 56 | 9 | 8 podcasts and video |
| F12 | 25 | 21 | 8 | 3 | 4 | 70 | 21 | 1 post or article, 7 podcasts and video |

### Trial dimensions

- Primary endpoint: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR): F1 (3 shared claims), F2 (1 shared claims), F6 (4 shared claims)
- Primary endpoint: Overall Survival (OS): F1 (4 shared claims), F2 (1 shared claims), F3 (2 shared claims), F6 (7 shared claims)
- Secondary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR): F2 (8 shared claims), F6 (1 shared claims)
- Secondary endpoint: Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR): F2 (12 shared claims)
- Secondary endpoint: Number of Participants Who Experienced One or More Adverse Events (AEs): F3 (17 shared claims), F4 (1 shared claims), F6 (1 shared claims)
- Secondary endpoint: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE): F3 (6 shared claims), F7 (2 shared claims)
- Population and setting: F6 (4 shared claims)
- The comparison: F3 (4 shared claims), F6 (3 shared claims)
- Safety and tolerability: F3 (27 shared claims), F4 (1 shared claims), F5 (1 shared claims)
- Design and conduct: F1 (2 shared claims), F3 (1 shared claims), F6 (19 shared claims)

## Abbreviations

- AE: adverse event
- BICR: blinded independent central review
- DOR: duration of response
- HCP: healthcare professional
- IO: immuno-oncology
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- ORR: objective response rate
- OS: overall survival
- PD-L1: programmed death-ligand 1
- PFS: progression-free survival
- RCC: renal cell carcinoma
- RECIST: Response Evaluation Criteria in Solid Tumors

## Examples from the report

Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.

- Medical oncologist, ex-US, identity checked against a staff page · podcast · Apr 2026 (finding F3): A medical oncologist does not think the trial's approach is for everybody because adding belzutifan brings different side effects, but expects some patients to choose the better efficacy despite those side effects.
- Physician, US, identity checked against NPI · video · Mar 2026 (finding F4): A physician regards belzutifan plus lenvatinib as a meaningful new option for post-PD-L1 RCC, while emphasizing patient selection and suggesting favorable- and intermediate-risk patients appear to gain the most.
- Physician, US, identity checked against NPI · podcast · Mar 2026 (finding F5): A physician might apply the same full-dose, fit-patient logic to lenvatinib–belzutifan in the future, without those dose reductions.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 17 sections | Paid |
| Verified statements with short source quotes and links | 1,422 | Paid |
| Who said each statement: the cited speakers | 92 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 61 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 75 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 22 | Free |
| Sources with links | 239 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 61 of the 92 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

22 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) | discussed | 14 | 13 |
| Primary endpoint: Overall Survival (OS) | discussed | 18 | 12 |
| Secondary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) | discussed | 12 | 12 |
| Secondary endpoint: Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) | discussed | 12 | 11 |
| Secondary endpoint: Number of Participants Who Experienced One or More Adverse Events (AEs) | discussed | 17 | 14 |
| Secondary endpoint: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | discussed | 8 | 7 |
| Population and setting | discussed | 21 | 12 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 21 | 11 |
| Safety and tolerability | discussed | 27 | 14 |
| Design and conduct | discussed | 21 | 10 |
| Speakers’ debate over adoption and the evidentiary weight of PFS versus OS | discussed | 16 | 15 |
| Speakers’ combination-versus-sequencing and component-contribution questions | discussed | 22 | 9 |
| Speakers’ interpretations of IMDC patterns and predictive-biomarker needs | discussed | 26 | 13 |
| Speakers’ patient-reported outcomes and patient-goal interpretations | discussed | 23 | 14 |
| Speakers’ prior-treatment, reimbursement and treatment-line preservation concerns | discussed | 30 | 14 |
| Earlier HIF-2α combination evidence and speakers’ development expectations | discussed | 29 | 18 |
| Post-IO alternatives, response urgency and trial-referral decisions | discussed | 41 | 9 |
| Post-PD-1 rechallenge, treatment withdrawal and local deferral of systemic switching | discussed | 45 | 8 |
| Belzutifan-associated anemia: speakers’ work-up, ESA use and counseling | discussed | 28 | 6 |
| Belzutifan-associated hypoxia: speakers’ monitoring and interruption practices | discussed | 26 | 7 |
| Belzutifan selection: speakers’ VHL-testing and broader profiling debate | discussed | 23 | 4 |
| Casdatifan and PEAK-1: alternative-development comparisons and their limits | discussed | 26 | 8 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 1059 statements · 74%** | | | |
| YouTube | 288 | 22 | 23 |
| X videos | 5 | 1 | 1 |
| Podcasts | 766 | 23 | 24 |
| **Posts · 341 statements · 24%** | | | |
| X threads | 301 | 171 | 365 |
| LinkedIn posts | 33 | 11 | 12 |
| Bluesky threads | 7 | 7 | 36 |
| **Primary sources · 22 statements · 2%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 21 | 3 | not screened |
| Registry (primary source, cited for context) | 1 | 1 | not screened |

- Screened window: 2020-10-23 to 2026-11-17
- Cited window: 2022-09-12 to 2026-11-14
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
- Registry: NCT04586231 (https://clinicaltrials.gov/study/NCT04586231)
- Study IDs: 6482-011 · MK-6482-011 (MSD) · jRCT2031210311 (jRCT(Japan Registry of Clinical Trials)) · 2024-510620-39-00 (EU CT) · U1111-1302-2815 (UTN) · 2020-002075-35
- Sponsor: Merck Sharp & Dohme LLC
- Collaborators: Eisai Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 747 (actual)
- Start: 2021-02-25 (actual)
- Primary completion: 2026-02-02 (actual)
- Primary endpoint: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) (Up to approximately 34 months)
- Primary endpoint: Overall Survival (OS) (Up to approximately 44 months)
- Intervention: Belzutifan (drug)
- Intervention: Lenvatinib (drug)
- Intervention: Cabozantinib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 2 matching sources (1 podcast, 1 X thread) could not be read and are not included.
- For 3 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a view on interpreting combination-treatment evidence and individual drug contributions after prior immunotherapy in advanced renal cell carcinoma; a view on emerging post-immunotherapy combinations for subsequent treatment selection in advanced renal cell carcinoma; a view on interpreting efficacy and survival evidence for combination therapy after checkpoint inhibitor progression in advanced renal cancer; a view on real-world evidence supporting cabozantinib as a sequencing option in previously treated advanced renal cell carcinoma; a view on how frontline regimen selection and tolerability shape subsequent treatment options in advanced renal cell carcinoma; a view on salvage kinase inhibition after immunotherapy progression versus upfront triplet therapy; a view on early anemia and hypoxia monitoring and supportive care during belzutifan treatment; a view on distinguishing reported evidence from personal clinical interpretation of combination therapy after immunotherapy in advanced kidney cancer; a view on exploratory biomarkers for selecting patients for belzutifan treatment in previously treated advanced renal cell carcinoma; a view on exploratory biomarkers that may inform patient selection for belzutifan treatment in renal cell carcinoma; a view on efficacy and tolerability requirements for combination treatment versus sequential therapy in advanced renal cell carcinoma; a view on belzutifan monotherapy efficacy, tolerability and quality of life as context for combination treatment after immunotherapy.
- 117 passages in 2 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 510 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 3 sources about other trials or topics are not included.
- The sources reviewed for this edition are not a representative survey of HCPs. Their number cannot establish the prevalence of a view, prescribing uptake or professional consensus.
- Some discussions appear in multiple recordings, summaries, reposts or quoted posts. Repetition and redistribution are not additional independent clinical endorsements.
- Some source material could not be read reliably, and portions of several long discussions were not fully assessed. Relevant views, qualifications or answers may therefore be missing.
- Discovery relied partly on trial identifiers and known names. Discussions using unnamed references, unusual abbreviations or different transcriptions may not have been found.
- Several passages cannot be attributed to a named individual with confidence. They remain observations made in the discussion and must not be counted as another participant agreeing or disagreeing with a named speaker.
- The material spans prospective expectations, interim interpretations, final-analysis discussions and approval-related reactions. Those time-specific views should not be combined into an apparent change of mind or treated as equally mature assessments.
- Speakers sometimes give different numerical summaries, study names, toxicity definitions, discontinuation denominators or descriptions of prior treatment. These remain attributed accounts; they are not harmonized into a single clinical dataset.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Descriptions of participation in development, presentation of the trial or investigator involvement are the sources’ own descriptions. Such views are not counted as independent external validation.
- An exploratory risk-group pattern, a biological hypothesis or a comparison across studies does not establish a predictive treatment interaction or comparative superiority. Several speakers explicitly make this distinction.
- Belzutifan monotherapy experience, supportive-care practices, other HIF-2α combinations and post-adjuvant decisions are included only as attributed context for the post-IO treatment question. Their outcomes and management approaches are not results or prescribing instructions for the LITESPARK-011 combination.
- No protocol document was listed in the ClinicalTrials.gov material available for this edition. The separately described protocol publication provides planned methods and rationale, not completed comparative outcomes.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-20 UTC: current edition
  - Routine maintenance: 2 fixes (names, counts, text):
    - 2026-11-20 UTC: The trial's name is spelled as its investigators write it, “LITESPARK-011” (NCT04586231), outside quotations (was “Litespark”, “Litespark-011”, “LITESPARK011”).
    - 2026-11-20 UTC: An editorial bracket follows a transcription-garbled trial name in quotations: “Littespark [LITESPARK]”.

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-20 UTC. No changes.

## Offer

- Size: Deep · 1,422 verified statements · 672 from 61 confirmed clinicians
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $3,400
- 6 months of updates: $4,900
- 12 months of updates: $6,800
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (75 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/litespark-011-nct04586231
- Agents: POST https://www.erudio.com/api/orders with {"report": "litespark-011-nct04586231", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=litespark-011-nct04586231

## Cite

Erudio Health. LITESPARK-011 (NCT04586231): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/litespark-011-nct04586231

## Questions

### How much does the LITESPARK-011 report cost?

One edition costs $1,950 (Deep · 1,422 verified statements · 672 from 61 confirmed clinicians). With updates: 3 months $3,400, 6 months $4,900, 12 months $6,800. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the LITESPARK-011 report cover?

1,422 statements from 239 sources (23 podcasts, 23 videos, 189 posts, 3 papers, 1 registry record), 672 of them from 61 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the LITESPARK-011 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "litespark-011-nct04586231" }) previews it and create_order({ "report": "litespark-011-nct04586231", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the LITESPARK-011 report?

Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/litespark-011-nct04586231.json
- Markdown: https://www.erudio.com/reports/litespark-011-nct04586231.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/litespark-011-nct04586231/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "litespark-011-nct04586231"}`
